Skip to main content

Market Overview

Homology Medicines Regains Global Rights To Novartis Ophthalmology Program

Share:

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing technology platform for an ophthalmic target.

  • Novartis had concluded the collaboration and licensing agreement with Homology announced in 2017 to pursue other opportunities in their pipeline.
  • The company has generated in vivo data in two different eye targets.
  • "AAVHSC vectors can edit the back of the eye, and we plan to share additional data from the ophthalmology program at a scientific meeting in May," said Arthur Tzianabos, President and CEO of Homology Medicines.
  • Price Action: FIXX shares were trading 3.54% higher at $11.12, and NVS shares were up 0.8% at $86.61 in market trading hours on the last check Monday.
 

Related Articles (NVS + FIXX)

View Comments and Join the Discussion!

Posted-In: ophthalmologyBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com